Second Quarter 2019 Financial Results

August 1, 2019

Agios Conference Call Participants

Prepared Remarks

Introduction

- KENDRA ADAMS, Vice President, External Communications & Investor Relations

Business Highlights

- JACKIE FOUSE, Ph.D., Chief Executive Officer

Clinical Development Progress

- CHRIS BOWDEN, M.D., Chief Medical Officer

TIBSOVO® Commercial Update

- DARRIN MILES, Senior Vice President, U.S. Commercial & Global Marketing

Second Quarter 2019 Financial Results

- ANDREW HIRSCH, Chief Financial Officer & Head of Corporate Development

Forward Looking Statements

This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Agios' plans, strategies and expectations for its and its collaborator's preclinical, clinical and commercial advancement of its drug development programs including TIBSOVO® (ivosidenib), IDHIFA® (enasidenib), vorasidenib, mitapivat, AG-270 and AG-636; the potential benefits of Agios' product candidates; its key milestones for 2019; its plans regarding future data presentations; its financial guidance regarding the period in which it will have capital available to fund its operations; and the potential benefit of its strategic plans and focus. The words "anticipate," "expect," "hope," "milestone," "plan," "potential," "possible," "strategy," "will," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios or its collaborators is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this presentation and various remarks we make during this presentation could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this presentation and various remarks we make during this presentation speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Business Updates

Jackie Fouse, Ph.D., Chief Executive Officer

agios

Building One of the Next Great Pharmaceutical Companies



2019 Key Milestones Position Agios for Long-term Value Creation



Clinical Development Progress

Chris Bowden, M.D., Chief Medical Officer

Agios Clinical Pipeline

IC = Intensive Chemotherapy

CLINICAL PROGRAMS	INDICATION	DRUG DISCOVERY	EARLY STAGE CLINICAL DEVELOPMENT	LATE STAGE CLINICAL DEVELOPMENT	REGULATORY SUBMISSION	APPROVED	PRIMARY RIGHTS
TIBSOVO® **ivosidenib** (IDH1m inhibitor)	R/R AML		Phase 1 Dose-Escalation and Expansion		EU	U.S.	agios
	Frontline AML Monotherapy		Phase 1 Dose-Escalation and Expansion			U.S.	
	IC Eligible Frontline AML		Phase 1b 7+3 Combo	Phase 3 HOVON 7+3 Combo			
	IC Ineligible Frontline AML		Phase 1/2 Azacitidine Combo	Phase 3 AGILE Azacitidine Combo			
	Cholangio		Phase 1 Dose-Escalation and Expansion	Phase 3 ClarIDHy			
	Glioma		Perioperative Study				
IDHIFA® **enasidenib** (IDH2m inhibitor)	R/R AML			Phase 3 IDHENTIFY	EU	U.S.	agios Celgene Agios U.S. Co-promotion and Royalty
	IC Eligible Frontline AML		Phase 1b 7+3 Combo	Phase 3 HOVON 7+3 Combo			
	IC Ineligible Frontline AML		Phase 1/2 Azacitidine Combo				
Mitapivat (PKR activator)	Transfusion Independent PK Deficiency		Phase 2 DRIVE PK	Phase 3 ACTIVATE			agios
	Transfusion Dependent PK Deficiency			Phase 3 ACTIVATE-T			
	Thalassemia		Phase 2 Study				
Vorasidenib (brain-penetrant, pan-IDHm inhibitor)	Glioma		Perioperative Study	Phase 3 Study Planned for 4Q 2019			agios
	Solid Tumors		Phase 1 Dose-Escalation and Expansion				
AG-270 (MAT2A inhibitor)	MTAP-deleted Tumors		Phase 1 Dose-Escalation and Expansion				Celgene agios Subject to Celgene Option Joint Worldwide Collaboration
AG-636 (DHODH inhibitor)	Lymphoma		Phase 1 Dose-Escalation				agios

Shifting the Current Treatment Paradigm for Patients with Newly Diagnosed IDH1m AML

~50K U.S. and EU Annual Newly Diagnosed AML Patients
IDH1/2m is ~20%

Intensive Therapy
~60-70% Treated Patients

Intensive therapy
+ novel therapies
(targeted & non-targeted)

Increase cure rate

Non-Intensive Therapy
~30-40% Treated Patients

Eligible for Combination Therapy

Combination of non-intensive therapy + novel therapies (targeted & non-targeted)

Prolong EFS/OS

Not Eligible for Combination Therapy

Single agent novel therapies (targeted & non-targeted)

Prolong EFS/OS

Untreated
Up to ~25% all Patients

Single agent novel therapies (targeted & non-targeted)

Clinical benefit

Sources: SEER. Cancer Stat Facts: AML 2015 and Epiphany EPIC oncology numbers; American Cancer Society. AML 2017.

Potential to Offer Clinical Benefit to Newly Diagnosed Patients Ineligible for Intensive Chemotherapy

~50K U.S. and EU Annual Newly Diagnosed AML Patients
IDH1/2m is ~20%

Intensive Therapy	Non-Intensive Combination Therapy	Non-Intensive Monotherapy

SINGLE AGENT TIBSOVO® FDA APPROVED IN NEWLY DIAGNOSED AML

TIBSOVO® indicated for use in adult patients with newly diagnosed AML with an IDH1 mutation who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Results from 28 Patients in the Phase 1 Study:

- Median age 77 years
- 79% had AML-MRC or therapy-related AML; 46% prior HMA
- Safety consistent previously reported data
- 29% CR rate
- 43% CR+CRh rate
- 58.3% of CR+CRh patients were in remission at 1 year after receiving treatment

 Sources: SEER. Cancer Stat Facts: AML 2015 and Epiphany EPIC oncology numbers; American Cancer Society AML 2017; TIBSOVO® U.S. Prescribing Information

Compelling Phase 1 Combination Data for Patients Ineligible for Intensive Chemo Suggests Potential to Extend EFS/OS

~50K U.S. and EU Annual Newly Diagnosed AML Patients
IDH1/2m is ~20%

Intensive Therapy	**Non-Intensive Combination Therapy**	Non-Intensive Monotherapy

PHASE 1 AZACITIDINE COMBO DATA

(TIBSOVO® cohort)

Received Breakthrough Therapy Designation

- Median age 76 years
- Safety consistent with previously reported data
- 78% ORR (18 of 23)
- 82% 12-month overall survival rate
- 70% CR+CRh rate (16 of 23)
- 61% CR rate (14 of 23)
- Median duration of CR (95% CI 9.3, NE) and CR+CRh (95% CI 12.2, NE) not reached

NEXT STEPS

AGILE PHASE 3 STUDY

Enrollment Expected to Complete in 2020

BROAD IST SUPPORT

VENCLEXTA® Combination
XOSPATA® Combination
BEAT AML Master Trial

Sources: SEER. Cancer Stat Facts: AML 2015 and Epiphany EPIC oncology numbers; American Cancer Society AML 2017; ASCO 2019; VENCLEXTA® is a registered trademark of Abbvie; XOSPATA® is a registered trademark of Astellas

Encouraging Phase 1 Data in Combination with Intensive Chemo Supports Label Enabling Phase 3 Study

~50K U.S. and EU Annual Newly Diagnosed AML Patients
IDH1/2m is ~20%

Intensive Therapy | **Non-Intensive Combination Therapy** | **Non-Intensive Monotherapy**

PHASE 1 7+3 COMBO DATA

(TIBSOVO® cohort)

- Median age 63 years
- 70% de novo; 30% sAML
- Safety consistent with previously reported data
- 91% CR+CRi/CRp rate for de novo patients (31 of 34)
- 80% CR+CRi/CRp rate for all patients (39 of 49)

NEXT STEPS

HOVON 150 AML / AMLSG 29-18 PHASE 3 STUDY
Trial initiated

BROAD IST SUPPORT
VYXEOS™ Combination

Sources: SEER. Cancer Stat Facts: AML 2015 and Epiphany EPIC oncology numbers; American Cancer Society AML 2017; ASCO 2018; ASH 2018; VYXEOS™ is a trademark of Jazz Pharmaceuticals

Phase 3 ClarIDHy Study Achieved Primary Endpoint, Demonstrating Statistically Significant Improvement in PFS

Safety Profile Consistent with Published Phase 1 Data in Patients with IDH1 Mutant Solid Tumors

Global Phase 3 Previously Treated Advanced IDH1m Cholangiocarcinoma (no more than 2 prior therapies)

2:1 Double Blind Randomization (n=186)

- **Ivosidenib Arm 500mg**
- **Placebo Arm**

Primary Endpoint: PFS

Crossover at time of progression

Secondary Endpoints: OS, ORR, safety, QoL

ClinicalTrials.gov Identifier: NCT02989857

Full data from the Phase 3 ClarIDHy study of TIBSOVO® in IDH1m advanced cholangiocarcinoma submitted for presentation at ESMO

Pivotal Path in WHO Grade II Glioma: Aim to Delay Progression to Chemotherapy and/or Radiotherapy



Registration-enabling Phase 3 study of vorasidenib to initiate by year-end 2019

Opportunity for Mitapivat to be the First Disease-Modifying Treatment for PK Deficiency



Sources: Estimated prevalence range from ~1:20K to ~1:485K Grace R et al. *Am J Hematol* 2015;90(9):825-30; [1]Mohrenweiser HW *PNAS* 1981;78(8):5046-50; [2]Carey PJ et al. *Blood* 2000;96(12):4005-6; [3]Beutler E & Gelbart T *Blood* 2000;95(11):3585-8; [4]deMedicis et al. *Hum Hered* 1992;42(3):179-83; data presented at ASH 2017

[1]Mean maximum hemoglobin increase of 3.4 g/dL in patients to had a >1.0 g/dL increase in haemoglobin on study

New data from the extension phase of the Phase 2 DRIVE PK study of mitapivat in adults with PK deficiency submitted for presentation at ASH

Mitapivat Path to Approval

ACTIVATE

- **~80 patients** treated for 6 months
- **Primary endpoint:** portion of patients achieving 1.5 g/dL Hb increase over multiple visits

ACTIVATE-T

- **Up to 40 patients,** minimum of 6 transfusions 1 year before enrollment
- **Primary endpoint:** reduction in transfusion burden over 6 months compared to patient's transfusion history

- **Disease awareness**
- **Improving path to diagnosis**
- **Patient voice**

Single Agent Dose-Escalation Complete; Advancing AG-270 to Next Phase of Clinical Development



ClinicalTrials.gov Identifier: NCT03435250

First clinical data from the Phase 1 submitted for presentation at NCI-AACR-EORTC

2019 Key Milestones & Data Presentations Position Agios for Long-term Value Creation

Key 2019 Milestones

- ✓ FDA approval and commercialization of monotherapy TIBSOVO® in untreated AML
- ✓ Initiate AG-636 Phase 1 dose-escalation trial in lymphoma in 1H 2019
- ✓ Complete AG-270 Phase 1 dose-escalation and select go forward dose
- Initiate expansion arms in the AG-270 Phase 1 study in Q3 2019
- Achieve proof-of-concept for mitapivat in thalassemia in 2H 2019
- Submit sNDA for TIBSOVO® in second line or later cholangiocarcinoma by YE
- Initiate glioma registration-enabling trial with vorasidenib by YE
- Complete enrollment in PK deficiency pivotal trials ACTIVATE-T and ACTIVATE by YE

Key Upcoming Data Presentations

- Full data from Phase 3 ClarIDHy trial of TIBSOVO® in IDH1m advanced cholangiocarcinoma submitted for presentation at ESMO
- Data from single agent dose-escalation portion of Phase 1 trial of AG-270 in MTAP-deleted tumors submitted for presentation at NCI-AACR-EORTC
- Data from IDH and PKR programs have been submitted for presentation at ASH, including:
  - New data from the extension phase of the Phase 2 DRIVE PK study of mitapivat in adults with PK deficiency
  - Important translational data from the Phase 1 study of TIBSOVO® and azacitidine in frontline AML

TIBSOVO® Commercial Update

Darrin Miles, Senior Vice President, U.S. Commercial & Global Marketing

agios

TIBSOVO® Q2 2019 Performance

$13.7M Net U.S. Sales of TIBSOVO®



~90% Academic and Community Physicians Testing for IDH1/IDH2 mutations

350 Unique Prescribers; Continue to Broaden Prescriber Base

Successful Launch in Frontline AML Following sNDA Approval in May

Market research as of February 2019; Agios estimates

Demonstrated Ability to Drive Commercial Performance During First Year of the R/R AML Launch





Agios estimates

Second Quarter 2019 Financial Results

Andrew Hirsch, Chief Financial Officer and Head of Corporate Development

agios

Second Quarter 2019 Financial Results

Statement of Operations	Three Months Ended 6/30/19	Three Months Ended 6/30/18
Total Revenue	$26.2M	$40.4M
Collaboration Revenue	9.8M	38.8M
TIBSOVO® Net Sales	13.7M	--
Royalty Revenue	2.7M	1.6M
Cost of Sales	0.3M	--
Research & Development Expense	107.4M	86.7M
Selling, General & Administrative Expense	32.4M	26.6M

Balance Sheet	6/30/19	12/31/18
Cash, Cash Equivalents and Marketable Securities	$624.0M	$805.4M

June 30, 2019 cash balance provides runway through at least the end of 2020

Q&A

agios